Drug or treatment

Tuvonralimab clinical trials

• 47Clinical trials
• 2New in 30 days
• 1Country

Newest trials

All recruiting trials (47)

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Neoadjuvant immunotherapy plus Nab-P-SOX for locally advanced gastric/GEJ cancer

  This phase 2, single-arm study tests a pre-surgery treatment that combines a PD-1/CTLA-4 bispecific antibody with nab-paclitaxel, oxaliplatin, and S-1 in adults with HER2-negative, locally advanced gastric or GEJ cancer.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07867392

• Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases

  This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07847359

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

• Iparomlimab and Tuvonralimab with Lenvatinib, Radiotherapy, and HAIC in HCC with PVTT

  This trial tests a multi-drug approach to see if it can control liver cancer that has grown into the portal vein in adults.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07776080

• First-line QL1706 plus Gemcitabine and Cisplatin for PD-L1–positive biliary tract cancer

  This study tests whether adding QL1706 to standard gemcitabine and cisplatin can help shrink tumors in adults with PD-L1–positive biliary tract cancer as a first treatment.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07733115

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• Iparomlimab plus tuvonralimab, with or without chemotherapy, for second-line and later recurrent or metastatic head and neck squamous cell carcinoma

  This will try whether combining two antibodies, iparomlimab and tuvonralimab, with or without chemotherapy helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after at least one systemic treatment.

  Recruiting The Second Affiliated Hospital of Hainan Medical University · Haikou, Hainan · NCT07546383

• Iparomlimab and Tuvonralimab with short-course radiotherapy and chemotherapy for locally advanced head and neck cancer

  This trial will test whether adding the dual PD-1/CTLA-4 antibody Iparomlimab–Tuvonralimab to hypofractionated radiotherapy and chemotherapy helps people with locoregionally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07447570

• PHOENIX: QL1706 plus chemo and bevacizumab in high PD-L1, driver-mutant non-squamous NSCLC

  This trial tests if adding QL1706 to chemotherapy and bevacizumab can help patients with PD-L1 high, driver-mutant non-squamous NSCLC after TKIs.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong,China and 1 other locations · NCT07416058

• Neoadjuvant QL1706 (Iparomlimab + Tuvonralimab) with chemotherapy for HR-positive, HER2-negative breast cancer

  This trial will test whether giving QL1706 (two immunotherapy antibodies) together with paclitaxel and carboplatin before surgery helps people with hormone receptor–positive, HER2‑negative breast cancer.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07396324

• Fruquintinib plus nab‑paclitaxel with iparomlimab and tuvonralimab for people with advanced gastric or GEJ cancer after immunotherapy

  This trial tests whether adding fruquintinib and two immune drugs (iparomlimab and tuvonralimab) to nab‑paclitaxel helps people with advanced gastric cancer whose disease progressed after first‑line immunotherapy.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07392346

• Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response

  This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07372079

• QL1706 (Iparomlimab + Tuvonralimab) with SOX chemotherapy for untreated advanced or metastatic gastric or gastroesophageal junction cancer

  This trial will test whether adding QL1706 (two immunotherapy drugs) to SOX chemotherapy helps people with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer get a better tumor response.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07315854

• Radiotherapy Plus CAPOX and Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

  This trial tests whether adding immunotherapy with chemotherapy and radiotherapy before surgery can improve how well locally advanced rectal cancer responds.

  Recruiting Phase 2 Zhongnan Hospital · Wuhan, Hubei · NCT07291401

• First-line treatment with iparomlimab and tuvonralimab plus chemotherapy for esophageal squamous cell carcinoma

  This will test whether adding two immunotherapy drugs, iparomlimab and tuvonralimab, to chemotherapy helps people with unresectable, recurrent, or metastatic esophageal squamous cell carcinoma as a first-line treatment.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07290010

• Iparomlimab + Tuvonralimab with apatinib and irinotecan for AFP-producing advanced stomach or gastroesophageal junction cancer

  This study will test whether combining two immune drugs (iparomlimab and tuvonralimab) with apatinib and irinotecan helps people with advanced AFP-producing stomach or gastroesophageal junction cancer after progression on first-line PD-1 plus chemotherapy.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07289997

• TACE with QL1706 around surgery for liver cancer that goes beyond Milan criteria

  This trial tests whether giving TACE together with QL1706 around the time of surgery is safe and helpful for adults with resectable hepatocellular carcinoma that exceeds Milan criteria.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07268131

• Neoadjuvant Tuvonralimab and Iparomlimab with GEMOX for resectable biliary tract cancer

  This trial tests whether giving Tuvonralimab and Iparomlimab together with GEMOX chemotherapy before surgery helps adults with resectable or borderline-resectable biliary tract cancer get better surgical and pathologic outcomes.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07267078

• Iparomlimab/Tuvonralimab with concurrent chemoradiation for locally advanced cervical cancer

  This trial will test whether adding QL1706 (iparomlimab/tuvonralimab), a combined anti‑PD‑1/anti‑CTLA‑4 antibody pair, to standard concurrent cisplatin chemoradiation is safe and helpful for people with HPV‑related locally advanced cervical cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07232654

• Iparomlimab and Tuvonralimab (QL1706) with CDK4/6 inhibitor and fulvestrant for HR-positive, HER2-negative advanced breast cancer

  This trial will test whether adding Iparomlimab and Tuvonralimab (QL1706) to a CDK4/6 inhibitor and fulvestrant helps women with hormone receptor–positive, HER2–negative advanced breast cancer get better tumor control or live longer.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07180160

• Neoadjuvant radiotherapy plus SOX chemotherapy with Iparomlimab and Tuvonralimab for resectable gastric and gastroesophageal junction adenocarcinoma

  This trial will test whether adding radiotherapy to pre-surgery SOX chemotherapy plus two immunotherapy drugs (Iparomlimab and Tuvonralimab) helps people with resectable, HER2‑negative gastric or gastroesophageal junction cancer.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Other (Non U.s.) · NCT07165847

• IB-FOLFIRI for BRAF V600E metastatic colorectal cancer

  This trial tests whether adding the immune drugs Iparomlimab and Tuvonralimab to bevacizumab and FOLFIRI helps adults with BRAF V600E metastatic colorectal cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07150247

• IParomlimab and Tuvonralimab with first-line therapy for MSI-H gastric cancer

  This phase 2 trial tests whether adding iparomlimab or tuvonralimab to standard first-line chemotherapy and PD-1/PD-L1 therapy helps people with MSI-H, recurrent or metastatic gastric cancer.

  Recruiting at 10 sites Phase 2 Peking University · Shijiazhuang, Hebei and 9 other locations · NCT07127822

• Iparomlimab and Tuvonralimab plus nimotuzumab for recurrent or metastatic nasopharyngeal carcinoma after first-line treatment failure

  This will try combining two immune-targeting drugs, iparomlimab and tuvonralimab, with the antibody nimotuzumab to see if it helps people with recurrent or metastatic nasopharyngeal cancer whose first-line cisplatin-based treatment has failed.

  Recruiting Phase 2 Sun Yat-sen University · Guangdong · NCT07101744

• QL1706 (iparomlimab + tuvonralimab) with TACE and lenvatinib for second-line treatment of unresectable intermediate-to-advanced liver cancer

  This test will try whether adding QL1706 (iparomlimab plus tuvonralimab) to TACE and lenvatinib helps people with unresectable intermediate-to-advanced hepatocellular carcinoma who progressed after PD-1/PD-L1 plus bevacizumab.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07099274

• Iparomlimab and Tuvonralimab with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma

  This trial will test whether adding two immunotherapy drugs, iparomlimab and tuvonralimab, to cetuximab helps people with recurrent or metastatic head and neck squamous cell carcinoma who have already failed at least two prior systemic treatments.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07090317

• Cryoablation with lenvatinib and QL1706 for advanced intrahepatic cholangiocarcinoma

  We will try freezing tumors (cryoablation) together with the drugs lenvatinib and QL1706 in people whose advanced intrahepatic cholangiocarcinoma has worsened after first-line treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07070700

• HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases

  This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07062055

• Pre-surgery iparomlimab and tuvonralimab with chemotherapy for locally advanced cervical cancer

  This phase 2 trial tests whether giving iparomlimab and tuvonralimab with chemotherapy before surgery helps people with locally advanced cervical cancer shrink their tumors and improve outcomes.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07055399

• Iparomlimab and tuvonralimab added to total neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer

  This study tests if adding the immunotherapies iparomlimab and tuvonralimab to total neoadjuvant chemoradiotherapy improves tumor response in people with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07026422

• Pre-surgery treatment with iparomlimab, tuvonralimab, and lenvatinib for liver cancer

  This trial will try a 9-week pre-surgery combination of two immune antibodies (iparomlimab and tuvonralimab) plus daily lenvatinib in people with resectable hepatocellular carcinoma who are at high risk of recurrence.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07014150

• Neoadjuvant iparomlimab and tuvonralimab before surgery for resectable hepatocellular carcinoma

  This study tests whether giving iparomlimab and tuvonralimab before surgery, then after surgery, can help prevent cancer from coming back in people with resectable liver cancer at high risk of recurrence.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06954116

• Combining iparomlimab and tuvonralimab with chemotherapy and radiation for cervical cancer

  This study is testing if combining two new drugs with chemotherapy and radiation can help people with locally recurrent cervical cancer live longer and feel better.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong Recruiting · NCT06942416

• Treatment for Intermediate Trophoblastic Tumors using Iparomlimab and Tuvonralimab

  This study is testing a new combination treatment for people with intermediate trophoblastic tumors to see if it helps them respond better and live longer.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06941766

• Spatially targeted radiation followed by shorter or standard radiotherapy with iparomlimab and tuvonralimab for relapsed bulky solid tumors

  This study will test whether targeted 'spatially fractionated' radiation followed by shorter or standard radiotherapy combined with two immunotherapy drugs (iparomlimab and tuvonralimab) is safe and helpful for adults with relapsed or refractory bulky solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT06936748

• Combining iparomlimab and tuvonralimab with chemotherapy for advanced gastric cancer

  This study is testing a new combination of two drugs with chemotherapy to see if it can help people with advanced gastric cancer feel better.

  Recruiting at 29 sites Phase 2 Qilu Hospital of Shandong University · Zhengzhou, Henan and 28 other locations · NCT06932068

• Assessing the effectiveness of a new drug combination for advanced colorectal cancer treatment

  This study is testing a new combination of four drugs to see if it can help people with advanced colorectal cancer who haven't had success with other treatments.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT06930118

• Combining radiotherapy with immunotherapy and chemotherapy for rectal cancer treatment

  This study is testing if a new combination of short-term radiotherapy, immunotherapy, and chemotherapy can help people with locally advanced rectal cancer do better before surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06911684

• Neoadjuvant therapy for esophageal cancer

  This study is testing a new combination of treatments for patients with advanced esophageal cancer to see if it can help shrink tumors before surgery.

  Recruiting Phase 2 Shandong Provincial Hospital · Jinan, Shandong · NCT06908382

• Perioperative iparomlimab and tuvonralimab with or without chemotherapy for resectable NSCLC

  This study will test whether giving the immunotherapy regimen QL1706 (iparomlimab and tuvonralimab) before and around the time of surgery, with or without platinum-based chemotherapy, helps people with resectable stage II–IIIB non-small cell lung cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06897046

• Combination of Iparomlimab and Tuvonralimab with Chemotherapy for Cervical Cancer

  This study is testing whether combining two new immune treatments with standard chemotherapy can help women with locally advanced cervical cancer respond better to treatment before surgery.

  Recruiting Phase 2 Obstetrics & Gynecology Hospital of Fudan University · Shanghai · NCT06878222

• Short-course radiotherapy followed by CAPEOX with iparomlimab and tuvonralimab for resectable MSS/pMMR locally advanced rectal cancer

  This trial will test whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to short-course radiation and CAPEOX chemotherapy helps patients with resectable locally advanced MSS/pMMR rectal cancer keep their rectum and avoid major surgery.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06864013

• Iparomlimab and Tuvonralimab (QL1706) plus SOX versus SOX alone for locally advanced gastric or gastroesophageal junction adenocarcinoma

  This trial will test whether adding the immunotherapy combination Iparomlimab and Tuvonralimab (QL1706) to standard SOX chemotherapy before and after surgery helps people with locally advanced gastric or gastroesophageal junction adenocarcinoma achieve complete tumor remission.

  Recruiting Phase 2 Shandong Provincial Hospital · Jinan, Shandong · NCT06829797

Quick answers

How many clinical trials of Tuvonralimab are recruiting right now?

47, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 43, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →